- Home
- COEP vs ALGS Comparison
COEP vs ALGS Comparison
Compare COEP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ALGS
- Stock Information
- Founded
- COEP 2017
- ALGS 2018
- Country
- COEP United States
- ALGS United States
- Employees
- COEP N/A
- ALGS N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- ALGS Health Care
- Exchange
- COEP Nasdaq
- ALGS Nasdaq
- Market Cap
- COEP 65.8M
- ALGS 53.0M
- IPO Year
- COEP N/A
- ALGS 2020
- Fundamental
- Price
- COEP $12.74
- ALGS $10.70
- Analyst Decision
- COEP
- ALGS Strong Buy
- Analyst Count
- COEP 0
- ALGS 2
- Target Price
- COEP N/A
- ALGS $60.00
- AVG Volume (30 Days)
- COEP 44.3K
- ALGS 76.3K
- Earning Date
- COEP 08-14-2025
- ALGS 08-06-2025
- Dividend Yield
- COEP N/A
- ALGS N/A
- EPS Growth
- COEP N/A
- ALGS N/A
- EPS
- COEP N/A
- ALGS N/A
- Revenue
- COEP $263,555.00
- ALGS $3,174,000.00
- Revenue This Year
- COEP N/A
- ALGS N/A
- Revenue Next Year
- COEP N/A
- ALGS $28.79
- P/E Ratio
- COEP N/A
- ALGS N/A
- Revenue Growth
- COEP N/A
- ALGS N/A
- 52 Week Low
- COEP $2.31
- ALGS $3.76
- 52 Week High
- COEP $14.70
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- COEP 56.79
- ALGS 72.04
- Support Level
- COEP $12.50
- ALGS $8.39
- Resistance Level
- COEP $14.09
- ALGS $11.70
- Average True Range (ATR)
- COEP 0.92
- ALGS 0.83
- MACD
- COEP -0.08
- ALGS 0.30
- Stochastic Oscillator
- COEP 55.49
- ALGS 84.07
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.